A well-defined patient audience is an important starting point for pharma media planning. But knowing who you want to reach is only half the equation. Understanding where that audience is most likely to be reached can be just as important, and those two decisions are more closely connected than traditional planning processes might suggest.
Too often, audience development and channel strategy happen in sequence. One team defines the target population, another evaluates media opportunities, and the resulting insights are assembled into a client recommendation. If the audience changes along the way, the process may start all over again.
But what if planners could evaluate channel opportunities while the audience was still taking shape?
Bringing channel propensity data into the audience-building process gives agencies an earlier, more complete view of their options. And when those insights are specific to a brand's intended patient population, rather than borrowed from broad demographic groups, they can lead to more informed decisions about audience precision, scale and media investment.
What Is Channel Propensity, and Why Does It Matter?
Channel propensity describes how likely a defined audience is to use or engage with particular media channels, based on available behavioral and media data. For pharma marketers, it provides valuable context for deciding where to invest. It's an important distinction from two other measures that shape audience strategy:
- Audience reach estimates the number of people or households potentially available to target.
- Audience quality (AQ) measures how closely an audience aligns with the intended patient population.
Each answers a different question. Together, they help planners understand not just whether an audience is relevant and reachable, but how those characteristics should inform the media strategy.
Why Demographic-Based Channel Planning Can Miss the Mark
Traditional channel planning often starts with a demographic profile. Planners examine media consumption patterns among people of a certain age, income or geography, then apply those insights to a more specific patient population. It's a reasonable starting point, but demographics don't always tell the whole story in healthcare.
Two patient populations with similar demographic characteristics may have very different clinical profiles, treatment experiences and media behaviors. Channel recommendations based on broad demographic patterns may therefore reflect people who resemble the desired audience without fully representing the patients a brand actually wants to reach.
A clinically informed, bottom-up approach reverses that process. Instead of adapting general consumer media patterns to a patient audience, planners begin with the clinical characteristics that define the brand's target population. They can then evaluate the consumer attributes and channel propensities associated with that specific audience.
Technologies such as OptimizeRx's Micro-Neighborhood® Targeting make this approach possible by combining de-identified clinical and consumer data at the ZIP-9 level. This creates privacy-safe, hyperlocal audiences, along with their associated media behaviors, grounded in real-world health signals rather than relying solely on modeled demographic proxies.
The distinction matters: Demographics remain useful, but they become supporting intelligence rather than a substitute for clinical relevance. That gives agencies a more specific, evidence-based foundation for their media recommendations.
What Happens to the Media Mix When You Prioritize Reach vs. Precision?
Every pharma media planner knows the tension between audience quality and scale. Tighten the criteria too far, and the audience may become difficult or expensive to reach. Broaden them too much, and the campaign risks reaching consumers who are less clinically relevant to the brand.
But changing the audience can affect more than its size and quality. It can also change which channels represent the strongest media opportunities. Consider a hypothetical brand developing a DTC campaign for a chronic migraine treatment.
- For an awareness campaign, the team might begin with a broader clinically relevant population, prioritizing scale to educate more potential patients about treatment options.
- For a conversion-focused campaign, the team might narrow its criteria to patients whose diagnosis and treatment histories indicate a closer fit with the brand's eligibility requirements.
The narrower audience may offer greater clinical concentration but fewer addressable consumers. That's a familiar trade-off. What's less obvious is how channel opportunities might shift between those audiences. The broader population might support one balance of CTV, online video, social and programmatic display. As the criteria become more selective, the relative propensity and addressable reach across those channels may change.
When channel insights are available alongside audience quality and reach, planners can explore those differences before committing to a strategy. Does expanding the audience create meaningful new channel opportunities? Does a more selective population support a different media allocation? Is the additional reach worth a reduction in audience quality?
Channel propensity won't answer every question or dictate the media mix. But it gives planners more relevant evidence for making those decisions, rather than relying on assumptions that may no longer reflect the intended audience.
A Better DTC Planning Process: Build, Evaluate and Refine
Access to audience-specific channel intelligence also changes how agencies approach consumer audience creation. Instead of treating the audience build as a one-time request, planners can use an iterative process to test different definitions and evaluate their implications while the strategy is still taking shape.
An integrated pharma media planning workflow, like the one available in OptimizeRx’s Natural Language Audience Builder (NLAB), brings four activities together:
- Define the patient population. Start with the brand's clinical eligibility criteria, such as diagnosis, medication use or treatment history.
- Evaluate audience quality and scale. Examine audience size and quality by decile to understand how tightening or expanding the criteria affects precision and reach.
- Explore channel opportunities. Review propensity and addressable reach across media channels for that specific population.
- Refine and compare. Adjust the audience definition, then reassess quality, scale and channel opportunities together to determine which approach best supports the campaign objectives.
The advantage is that each insight can inform the next decision. A high-quality audience might reveal limited reach in a priority channel. A broader segment might create more media opportunities but dilute clinical relevance. When these trade-offs are visible early, planners can explore alternatives without starting the audience and media planning processes over again.
From Audience Intelligence to Client-Ready Media Plans
For agencies, the benefits extend beyond speed. Client recommendations become more compelling when planners can explain not just what they recommend, but why.
Audience-specific channel insights help teams demonstrate how clinical relevance, reach and media opportunities influenced their recommendations. They can show which alternatives were considered, why certain channels were prioritized and how the proposed strategy supports the brand's objectives. That means faster refinement, more informed channel selection and stronger rationale behind media investments.
Importantly, this approach doesn't replace the expertise agencies bring to media strategy. It makes that expertise more valuable by giving planners better information, earlier in the process, and more opportunities to test their assumptions.
Better Media Plans Start with Better Questions
The strongest media plans aren't necessarily built around the largest audiences or the narrowest targeting criteria. They're built on informed decisions about how audience definition, channel opportunity and campaign objectives work together.
Bringing channel propensity into audience creation gives planners the visibility to make those decisions earlier, while there's still room to explore and improve the strategy.
With tools like NLAB connecting these capabilities in a single workflow, agencies have an opportunity to do more than build media plans faster. They can build plans that are more informed, more adaptable and easier to defend.
Explore how NLAB connects audience creation and media planning.
